Acorah Software Products - Accounts Production 16.3.350 false true 29 February 2024 1 March 2023 false 1 March 2024 28 February 2025 28 February 2025 12468870 Mr M W Harvey Mrs F L Harvey iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12468870 2024-02-29 12468870 2025-02-28 12468870 2024-03-01 2025-02-28 12468870 frs-core:CurrentFinancialInstruments 2025-02-28 12468870 frs-core:Non-currentFinancialInstruments 2025-02-28 12468870 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2025-02-28 12468870 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 12468870 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2024-02-29 12468870 frs-core:CapitalRedemptionReserve 2025-02-28 12468870 frs-core:ShareCapital 2025-02-28 12468870 frs-core:RetainedEarningsAccumulatedLosses 2025-02-28 12468870 frs-bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 12468870 frs-bus:FilletedAccounts 2024-03-01 2025-02-28 12468870 frs-bus:SmallEntities 2024-03-01 2025-02-28 12468870 frs-bus:AuditExempt-NoAccountantsReport 2024-03-01 2025-02-28 12468870 frs-bus:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 12468870 frs-core:UnlistedNon-exchangeTraded 2025-02-28 12468870 frs-core:UnlistedNon-exchangeTraded 2024-02-29 12468870 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-02-29 12468870 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-02-28 12468870 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-02-29 12468870 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-02-28 12468870 frs-bus:Director1 2024-03-01 2025-02-28 12468870 frs-bus:Director2 2024-03-01 2025-02-28 12468870 frs-core:CurrentFinancialInstruments 1 2025-02-28 12468870 frs-countries:EnglandWales 2024-03-01 2025-02-28 12468870 2023-02-28 12468870 2024-02-29 12468870 2023-03-01 2024-02-29 12468870 frs-core:CurrentFinancialInstruments 2024-02-29 12468870 frs-core:Non-currentFinancialInstruments 2024-02-29 12468870 frs-core:CapitalRedemptionReserve 2024-02-29 12468870 frs-core:ShareCapital 2024-02-29 12468870 frs-core:RetainedEarningsAccumulatedLosses 2024-02-29 12468870 frs-core:CurrentFinancialInstruments 1 2024-02-29
Registered number: 12468870
GLP Pharma Ltd
Unaudited Financial Statements
For The Year Ended 28 February 2025
Alexander Myerson & Co Limited
Alexander House
61 Rodney Street
Liverpool
Merseyside
L1 9ER
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 12468870
2025 2024
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 314,047 -
Investments 5 3,829,330 3,829,330
4,143,377 3,829,330
CURRENT ASSETS
Debtors 6 4,002 -
Cash at bank and in hand 12,849 2,505
16,851 2,505
Creditors: Amounts Falling Due Within One Year 7 (950,193 ) (1,099,824 )
NET CURRENT ASSETS (LIABILITIES) (933,342 ) (1,097,319 )
TOTAL ASSETS LESS CURRENT LIABILITIES 3,210,035 2,732,011
Creditors: Amounts Falling Due After More Than One Year 8 (2,373,456 ) (1,924,091 )
NET ASSETS 836,579 807,920
CAPITAL AND RESERVES
Called up share capital 9 2 2
Capital redemption reserve 1 1
Profit and Loss Account 836,576 807,917
SHAREHOLDERS' FUNDS 836,579 807,920
Page 1
Page 2
For the year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr M W Harvey
Director
6 June 2025
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
GLP Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12468870 . The registered office is 61 Rodney Street, Liverpool, Merseyside, L1 9ER.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Freehold 2% on cost
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2024: 3)
2 3
4. Tangible Assets
Land & Property
Freehold
£
Cost
As at 1 March 2024 -
Additions 320,456
As at 28 February 2025 320,456
Depreciation
As at 1 March 2024 -
Provided during the period 6,409
As at 28 February 2025 6,409
Net Book Value
As at 28 February 2025 314,047
As at 1 March 2024 -
5. Investments
Unlisted
£
Cost
As at 1 March 2024 3,829,330
As at 28 February 2025 3,829,330
Provision
As at 1 March 2024 -
As at 28 February 2025 -
...CONTINUED
Page 3
Page 4
Net Book Value
As at 28 February 2025 3,829,330
As at 1 March 2024 3,829,330
6. Debtors
2025 2024
£ £
Due within one year
Directors' loan accounts 4,002 -
7. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Bank loans and overdrafts 75,000 75,000
Green Lane Pharmacy Limited 875,193 1,019,826
Directors' loan accounts - 4,998
950,193 1,099,824
8. Creditors: Amounts Falling Due After More Than One Year
2025 2024
£ £
Bank loans 2,373,456 1,924,091
9. Share Capital
2025 2024
£ £
Allotted, Called up and fully paid 2 2
Page 4